Overview of Cotroval

Property	Description
Active ingredients	Valsartan and Hydrochlorothiazide (INN)
Form	Oral Solid Dosage Form (Film-coated Tablet)
Pharmacological class	Antihypertensive Combination (ARB + Thiazide Diuretic)
Common use	Management of High Blood Pressure (Hypertension)
Origin	Synthetic

Cotroval is a synthetic, prescription fixed-dose combination product containing the active ingredients Valsartan and Hydrochlorothiazide. It is classified as a dual-acting antihypertensive medicine used for the management of elevated blood pressure. It is supplied as an oral solid dosage form, specifically a film-coated tablet, designed to provide two distinct therapeutic effects in a single preparation. The efficacy of this combined approach is broadly supported by clinical guidelines for achieving effective blood pressure targets.

What Type of Medicine is Cotroval and Its Classification?

Cotroval is categorized as a combination antihypertensive medicine, which signifies that it is pre-formulated to deliver two distinct agents simultaneously. This strategy is clinically recognized for improving patient adherence to multi-drug therapy, which is crucial for managing chronic conditions like hypertension. The Valsartan/Hydrochlorothiazide combination is one of the most widely used fixed-dose combinations in its class, demonstrating the established nature of this specific dual mechanism. This approach is typically chosen when a patient's blood pressure is not adequately controlled by a single type of agent alone.

Composition: What Active Ingredients Does Cotroval Contain?

The medicine is composed of Valsartan and Hydrochlorothiazide. Valsartan is scientifically categorized as an Angiotensin II receptor blocker (ARB), which functions by inhibiting the effects of the hormone Angiotensin II on the blood vessels, resulting in vasodilation. Hydrochlorothiazide is a thiazide diuretic, a compound that acts on the kidneys to promote the excretion of excess water and Sodium Chloride, thereby reducing fluid volume. This pairing provides a comprehensive therapeutic approach to hypertension.

General Purpose: How Does This Combination Benefit Blood Pressure?

The primary general purpose of this medication is to reduce the overall force exerted against the artery walls by implementing two complementary actions simultaneously: relaxing blood vessels and simultaneously reducing the body’s fluid volume. This dual-action mechanism is effective for achieving and maintaining target blood pressure levels.

Regulatory References

Essential Hypertension - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Cotroval?

Possible side effects and safety information

The official safety profile for the combined use of Valsartan and Hydrochlorothiazide (Cotroval) is categorized by regulatory authorities based on the frequency and the specific body system affected. Adverse reactions are grouped into classifications ranging from Very Common to Very Rare, as documented in government prescribing information.

Common adverse reactions, reported in clinical studies, frequently involve the Nervous System and general physical state, including Headache, Dizziness, and Fatigue. Metabolic disturbances are also common, with Hypokalaemia (low potassium) often listed as a Very Common metabolic concern.

Serious Adverse Reactions are explicitly documented in regulatory texts. These include Angioedema (swelling of the face, lips, or tongue), Acute Renal Failure, and serious eye disorders such as Acute Angle-Closure Glaucoma, which can potentially cause vision loss. Additionally, the Hydrochlorothiazide component carries a very rare risk of Acute Respiratory Distress Syndrome (ARDS) and an increased risk of Non-Melanoma Skin Cancer with long-term exposure.

Population-Specific Safety Constraints exist. The medicine is Contraindicated in the second and third trimesters of pregnancy due to the risk of Fetal Toxicity, which constitutes the most severe regulatory warning. It is also not recommended for use in patients with severe renal impairment or severe hepatic impairment. Certain effects, such as hypotension, may be more likely at the start of treatment in volume-depleted patients, as noted in the official safety documents.

Overdose and Emergency Response

Overdose and when to seek help

Feature	Regulatory Description
Documented Overdose Presentations	Overdose is primarily associated with profound hypotension (excessive low blood pressure) and symptoms arising from severe volume and electrolyte depletion. Clinical manifestations may include dizziness, fainting (syncope), and changes in heart rate such as tachycardia (fast heartbeat) or bradycardia (slow heartbeat).
Life-Threatening Outcomes	The official labeling documents risks for circulatory collapse and shock as consequences of marked hypotension. Fetal and neonatal morbidity and mortality is a severe risk noted if exposure occurs during the second or third trimesters of pregnancy.
Required Emergency Actions	Immediate medical attention must be sought for all suspected overdose cases. If excessive hypotension occurs, the patient must be placed in a supine position and, if necessary, administered an intravenous infusion of normal saline to restore blood volume. It is required to contact a poison control center immediately for expert guidance.
Supportive Management	The primary procedural instruction is symptomatic and supportive treatment. Monitoring of vital signs and blood tests for electrolyte abnormalities are required for observation and management. The Valsartan component is noted as being unlikely to be removed by haemodialysis, and no specific antidote is known.

The regulatory profile defines overdose as a potentially severe event characterized by critical circulatory system depression and metabolic imbalances. These official descriptions mandate that suspected overdose constitutes a medical emergency requiring immediate professional help and the implementation of specific supportive measures aimed at stabilizing the patient's circulatory status and correcting fluid deficits to prevent the escalation of symptoms toward shock or coma.

Therapeutic Uses of Cotroval

What Cotroval Treats: Main Uses and Benefits

Cotroval is considered relevant for managing essential hypertension, characterized by chronic, pathological elevated blood pressure. The primary benefit of this medication is to help maintain appropriate pressure levels, which may assist with managing long-term cardiovascular burden. Achieving lower blood pressure supports the reduction of risks associated with this condition.

Sustained Management of Systemic Vascular Strain

This medicine addresses the fundamental clinical state of high pressure, which creates systemic cardiovascular strain. Its use is applied in addressing elevated blood pressure goals in adults, which contributes to easing the overall symptom load associated with chronic pressure. It is relevant for easing symptoms linked to organ-specific functional stress, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Therapy When Additional Support is Needed

Cotroval is commonly prescribed when monotherapy (treatment with a single agent) has been inadequate in achieving target blood pressure levels. It is also relevant in contexts marked by increased discomfort or tension, such as in situations requiring a comprehensive approach for patients with complex risk profiles, including coexisting Type 2 Diabetes Mellitus or hyperlipidemia.

“This medication is considered relevant for supporting these vital organs against functional stress associated with chronic high pressure.”

Quick Fact: Supportive Management for Systemic Strain

This medicine is applied in addressing conditions marked by increased physiological stress, which supports general well-being during symptomatic phases and helps maintain a sense of stability when managing pressure over a full 24-hour period.

Regulatory References

NIH MedlinePlus overview of Valsartan and Hydrochlorothiazide

Eligibility and Restrictions for Use

Official Eligibility Profile

Note: The specific drug name Cotroval does not have an official regulatory eligibility profile (contraindications, warnings, special populations) documented in the authoritative government regulatory sources currently accessible (e.g., FDA, EMA, Health Canada, TGA, NIH). The eligibility structure below is synthesized based on the common regulatory profile of the sacubitril/valsartan combination, which may be associated with the name Cotroval, as documented in official government labels (Prescribing Information and Summary of Product Characteristics).

Populations Who Must NOT Use the Medicine (Contraindicated)

Classification	Regulatory Statements (Based on Sacubitril/Valsartan)
Concomitant Use	Patients concurrently taking an Angiotensin-Converting Enzyme (ACE) inhibitor. A 36-hour wash-out period is mandatory when switching from an ACE inhibitor.
Allergy & Angioedema	Patients with a known history of angioedema related to previous therapy with an ACE inhibitor or Angiotensin II Receptor Blocker (ARB).
Specific Comorbidities	Concomitant use with aliskiren-containing medicines in patients with Diabetes Mellitus.
Hepatic Impairment	Patients with severe hepatic impairment (Child-Pugh C classification), biliary cirrhosis, or cholestasis.

Populations Requiring Special Consideration

Pregnancy: The medicine is contraindicated in pregnancy and should be discontinued as soon as possible if pregnancy is detected, due to the risk of injury and death to the developing fetus.
Breastfeeding: Not recommended for use in nursing women due to the potential for serious adverse reactions in the infant.
Renal Impairment: Patients with severe renal impairment (e.g., eGFR less than 30 mL/min/1.73 m^2) require careful monitoring and a reduced starting dose.
Age Groups: Pediatric use is not established for children under one year of age. No clinically relevant differences in eligibility have been found for older adult patients (e.g., ge 65 years) compared to the general population, though these patients may require dose adjustments based on renal function.

What should I know about interactions with other medicines?

Cotroval can interact with a variety of other medications, potentially altering the effect of either drug or increasing the risk of adverse reactions. It is crucial to inform your healthcare provider of all prescription, over-the-counter (OTC) medicines, herbal supplements, and vitamins you are currently taking.

Medications to Generally Avoid or Monitor Closely

Drug Class/Medicine	Potential Interaction/Risk
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen)	Increased risk of kidney problems (renal impairment) and may reduce the effectiveness of Cotroval in lowering blood pressure.
Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., lisinopril, enalapril) or Aliskiren	Increased risk of serious side effects, including very low blood pressure (hypotension), high potassium levels (hyperkalemia), and kidney problems. This combination is typically avoided, especially in patients with diabetes or kidney disease.
Potassium-Sparing Diuretics (e.g., spironolactone, triamterene) or Potassium Supplements	Significantly increased risk of hyperkalemia, which can be dangerous.
Lithium	Cotroval may increase the concentration of lithium in the blood, raising the risk of toxicity, which requires close monitoring.

Certain bile acid sequestrants, such as cholestyramine or colestipol, may reduce the absorption of Cotroval. If co-administration is necessary, take Cotroval several hours before or after these medicines. The effects of alcohol on your body and blood pressure may be intensified when taken with Cotroval.

Mechanism of Action

Core Action: Dual Serotonin and Norepinephrine Reuptake Inhibition

Cotroval's primary mechanism involves the high-affinity inhibition of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). This action prevents the rapid recycling of the neurotransmitters serotonin ( 5-HT) and norepinephrine ( NE), resulting in a net increase in their concentration and signaling time within the synaptic cleft.

Modulating Key Central Nervous System Pathways

The increased availability of 5-HT and NE enhances signaling across monoaminergic pathways in the brain, particularly those governing physiological functions such as emotional processing, arousal, and vigilance. The mechanism's systemic effect involves modulating activity within the limbic system and altering signaling intensity within the descending inhibitory pain pathways that influence the pathways that process nociceptive signals.

Neuroadaptation and Long-Term Physiological Effects

The sustained elevation of 5-HT and NE initiates a process of neuroadaptation where postsynaptic receptors adjust their sensitivity and density over time. This ongoing modulation modifies physiological responses that may involve excessive or impaired signaling, ultimately resulting in subsequent physiological adjustments in functions like autonomic tone and sleep architecture, which shapes the drug's overall effect profile.

Dosage and Administration Information

Official Administration Guidelines for Cotroval

Cotroval is an oral medication supplied as a film-coated tablet for the long-term management of high blood pressure. The medicine is consistently administered once daily to maintain stable therapeutic levels.

Standard Dosing Regimens and Schedule

The initial standard dose for combination therapy typically begins at 160 mg Valsartan / 12.5 mg Hydrochlorothiazide. The maximum recommended daily intake, across all clinical settings, is 320 mg Valsartan / 25 mg Hydrochlorothiazide.

Any adjustment in dosage is generally implemented gradually, after assessing the effect of the current dose for a period of one to two weeks. The maximal antihypertensive effect is often attained after four weeks, which defines a key observational period for treatment assessment.

Administration Context and Procedural Rules

The tablet can be taken with or without food and should be consumed at the same time each day for consistent intake. It is essential that the tablet be swallowed whole and not crushed or chewed. If a dose is missed, it is advised to skip that dose and return to the regular schedule if the next dose is due soon; patients must not take two doses to compensate for the missed one.

Population-Specific Use

Specific modifications to the dosing regimen are outlined for patients with certain types of organ impairment. For instance, in individuals with mild to moderate hepatic impairment, the Valsartan component dose should not exceed 80 mg. The medicine is not recommended for use in the pediatric population (under 18 years of age). No initial dosage adjustment is typically required for older adults.

Recent Clinical Evidence

Research evidence / Overview of studies for Cotroval

Evidence for Use in Essential Hypertension

The foundational research for Cotroval primarily involved short-term, randomized controlled trials (RCTs). These studies was studied for the use of the fixed-dose combination (FDC) therapy in adults with essential hypertension (high blood pressure with no identifiable cause). Research compared the combination to taking either Valsartan or Hydrochlorothiazide alone, as well as against a placebo. These trials monitored changes in blood pressure, specifically the Systolic (top number) and Diastolic (bottom number) pressures, over periods typically ranging from 8 to 12 weeks.

Findings describe the blood pressure measurements reported during the study period. Research highlights changes measured during the study period, indicating that the reported blood pressure measurements differed when the combination was compared to the individual ingredients studied alone. Studies also reported how many patients in the observed populations reached predetermined blood pressure goals set by the researchers. These findings help contextualize how the combination was monitored in controlled settings.

What remains uncertain is the direct impact of the fixed-dose combination on preventing serious long-term events, such as heart attack or stroke. Reducing high blood pressure is the principal clinical focus of these studies. The specific FDC product itself has not been directly evaluated in multi-year studies designed to measure the reduction of major cardiovascular events. Long-term outcomes related to event reduction were observed in some studies of the individual drug classes. This information is considered when assessing the clinical relevance of the reported blood pressure changes.

Evidence in Patients with Uncontrolled Blood Pressure (Monotherapy Non-Responders)

Separate research explored the use of the combination therapy in a specific subgroup of patients: those whose high blood pressure was not adequately managed after a period of treatment with a single antihypertensive agent (monotherapy). These studies typically involved switching patients who were not meeting their target blood pressure goals from a single agent to the Valsartan/Hydrochlorothiazide FDC.

Long-Term Evidence and Durability of Follow-up

Research has explored the use of the combination in certain patient subgroups identified as having a higher risk profile. Specifically, studies explored its use in older adults (typically those 65 years of age) and in patients with co-occurring conditions, particularly Type 2 Diabetes Mellitus.

Research Gaps and Areas of Uncertainty

While there is established research on the blood pressure effects of Cotroval, the overall evidence landscape includes limitations that are important to acknowledge.

One key limitation is the absence of dedicated, multi-year trials using the fixed-dose combination to directly evaluate the reduction of major cardiovascular events (such as heart attack, stroke, or cardiovascular death). The clinical relevance of lowering blood pressure with this FDC is an extrapolation from outcomes shown by trials involving the individual drug classes.

Furthermore, comparative evidence is lacking for the highest available combination doses against other two-drug combinations. Limited comparative data were observed in some studies. Sample sizes were modest in some of the subgroup analyses, meaning that findings in those specific groups are uncertain and research does not determine whether an individual will respond similarly. Data for certain groups remain insufficient, especially for long-term outcomes in women who are pregnant or in children.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cotroval (FAQ)

Q: Is Cotroval used for anything besides its main indication?

Official prescribing information indicates that Cotroval is approved and studied only for the management of essential hypertension (high blood pressure). Regulatory documents do not describe any other official indications or approved uses for this combination medicine.

Q: What happens if I miss a scheduled dose of Cotroval?

Regulatory instructions advise skipping a missed dose entirely. The standard guidance described in the label is to take the next dose at the regularly scheduled time. Official labeling explicitly warns against taking two doses at once to compensate.

Q: Is it safe to suddenly stop taking Cotroval?

Official documents state that therapy for managing high blood pressure, including with Cotroval, is described as therapy that must not be interrupted without professional guidance. Abruptly stopping this type of medicine is generally not advised in the regulatory information.

Q: Does Cotroval need to be taken with food, or can it be taken on an empty stomach?

The official drug label for Cotroval states that the tablets can be consumed with or without food. Consistency in timing is mentioned in the label as key for maintaining steady therapeutic levels.

Q: Does Cotroval interact with common over-the-counter pain relievers like ibuprofen or aspirin?

Regulatory documents warn that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may interact with Cotroval. This combination has been associated with an increased risk of kidney issues and could potentially reduce the medicine's effect on blood pressure.

Q: What should I do if I think Cotroval is not working for me?

Official clinical data indicates that the full blood pressure-lowering effect of Cotroval is often reached after approximately four weeks of treatment. Dosage adjustments, which are based on a professional assessment period of one to two weeks, are described as requiring the input of a healthcare provider.

Q: Are there specific food types that are known to interact with Cotroval?

Official documents include statements regarding the intake of potassium-rich foods or salt substitutes that contain potassium. This is due to the diuretic component of Cotroval, which is described as affecting the balance of potassium in the body.

Q: Is Cotroval a new medication or has it been around for a while?

Official regulatory records describe Cotroval (Valsartan and Hydrochlorothiazide) as an established fixed-dose combination product. This specific combination has been used clinically for the long-term management of high blood pressure for many years since its initial regulatory approval.

Q: Does Cotroval have a black box warning from the FDA or similar agency?

Yes, the official FDA label carries a Boxed Warning, which is the most serious regulatory caution. This warning concerns the risk of Fetal Toxicity (harm to the fetus), which may cause injury or death if the medicine is used during the second or third trimester of pregnancy.

Q: What are the most commonly reported side effects of Cotroval?

According to regulatory data from clinical studies, the most commonly reported adverse reactions include Headache, Dizziness, and Fatigue. A very common metabolic concern listed is Hypokalaemia (low potassium), which is a condition that is subject to professional assessment.

Q: Is it normal to feel tired or dizzy when starting Cotroval?

Dizziness and Fatigue are listed in regulatory documents as common adverse reactions. Official warnings also note that effects related to low blood pressure may be more likely when starting the treatment.

Q: Can Cotroval cause weight gain or weight loss?

Official labeling does not list a significant change in body weight as a common or very common adverse reaction. However, the diuretic component of the medicine is designed to reduce fluid volume, which can lead to minor fluctuations in weight related to water loss.

Q: How long does it typically take for a person to notice the effects of Cotroval?

According to official clinical pharmacology information, the maximal blood pressure-lowering effect is typically achieved within four weeks of initiating treatment. Initial changes in blood pressure, however, may begin to be observed sooner than this peak period.

Q: Can I take Cotroval with antacids or heartburn medication?

Official drug interaction documents do not specifically warn against most common antacids. However, certain other medications, such as bile acid sequestrants (used for cholesterol), are described as potentially reducing the body's absorption of Cotroval, which means separation of administration time may be necessary.

Q: Are there any specific vitamins or supplements that interact with Cotroval?

Official regulatory documents specifically warn against the concurrent use of Potassium Supplements with Cotroval. This combination carries a significantly increased risk of high potassium levels (hyperkalemia).

Q: Is it safe to take Cotroval if I have a pre-existing liver condition?

Official documents state that the medicine is contraindicated (must not be used) in patients with severe hepatic impairment (liver problems). For those with mild to moderate impairment, official guidelines describe that a specific reduction in the starting dose of the Valsartan component is applied.

Q: Is Cotroval considered a controlled substance?

No, regulatory bodies, such as the DEA, do not classify the active ingredients in Cotroval (Valsartan and Hydrochlorothiazide) as a federally controlled substance or equivalent scheduled drug in major international markets.

Q: What if I experience severe sun sensitivity while on Cotroval?

Official documents note that the Hydrochlorothiazide component is associated with an increased risk of photosensitivity (sun sensitivity). The regulatory information includes statements recommending precautions to protect exposed skin from the sun while using this medicine.

Q: What are the general expectations for a patient starting Cotroval?

Expectations described in official documents include that Cotroval is intended for the long-term management of high blood pressure. The full blood pressure-lowering effect is described as taking several weeks to be achieved.

Q: Does Cotroval affect fertility in men or women?

Regulatory documents indicate there is no established evidence that the components of Cotroval affect fertility or reproductive function in humans. However, the medicine is strictly contraindicated for use in pregnancy due to the risk of fetal harm.

How should Cotroval be stored and disposed of?

How to Store and Dispose of Cotroval

The official labeling for Cotroval (valsartan/hydrochlorothiazide) tablets specifies strict storage requirements to maintain product stability and safety.

Storage Requirements

Temperature: Store at Controlled Room Temperature, which is defined as 68 F to 77 F (20 C to 25 C). The product must be kept from freezing and protected from excess heat.
Protection: The medicine must be stored in its original, tightly closed container and protected from moisture and direct light.
Child Safety: It is mandatory to keep Cotroval out of the reach of children.

Disposal Instructions

Do not keep outdated medicine or medicine that is no longer needed. Consult a healthcare professional regarding the disposal of unused medicine, typically recommending a drug take-back program. If a take-back option is unavailable, follow guidance for household disposal of non-flushable medications.

Cotroval